- KERX has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $61.1 million.
- KERX is down 3% today from today's close.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in KERX with the Ticky from Trade-Ideas. See the FREE profile for KERX NOW at Trade-Ideas More details on KERX: Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of renal disease in the United States. Currently there are 8 analysts that rate Keryx Biopharmaceuticals a buy, 1 analyst rates it a sell, and none rate it a hold. The average volume for Keryx Biopharmaceuticals has been 2.3 million shares per day over the past 30 days. Keryx has a market cap of $1.3 billion and is part of the health care sector and drugs industry. The stock has a beta of 4.36 and a short float of 22% with 4.21 days to cover. Shares are up 4.1% year-to-date as of the close of trading on Friday. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.